Chronic Delta Hepatitis Clinical Trial
— LOWR-5Official title:
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected With Hepatitis Delta Virus (LOWR-5)
A Phase 2b, Open-Label, Randomized Study of the Safety, Tolerability, and Pharmacodynamic Activity of Lonafarnib With or Without Ritonavir in Patients Chronically Infected with Hepatitis Delta Virus
| Status | Not yet recruiting |
| Enrollment | 60 |
| Est. completion date | |
| Est. primary completion date | December 2018 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 18 Years to 65 Years |
| Eligibility |
Inclusion Criteria: 1. Willing and able to comply with study procedures and provide written consent 2. 18 - 65 years old 3. Body mass index (BMI) of = 18 kg/m2 and weighs = 45 kg 4. CHD infection of at least 6 months' duration documented by a positive HDV antibody (Ab) test and HDV RNA = 3 log10/mL by qPCR at study entry 5. Serum ALT > upper limit of the normal range (ULN) and < 10 × ULN 6. Liver biopsy within 12 months of Day 1 demonstrating evidence of chronic hepatitis. If no liver biopsy is available, the patient must be willing to consent to and have no contraindication to liver biopsy 7. ECGs demonstrating no acute ischemia or clinically significant abnormality and a QT interval corrected for heart rate (QTcF) < 450 ms for male patients and < 460 ms for female patients 8. Dilated retinal examination = 1 year before screening: For patients with diabetes, hypertension, or other risk factors for retinal disease, performed by a licensed ocular specialist; for all other patients, a normal retinal examination as assessed by the investigator or a licensed ocular specialist 9. Female patients of childbearing potential and male patients with partners of childbearing potential must agree to use adequate methods of contraception during the study and for 90 days after the last dose of study drug. Female patients of childbearing potential are all those except patients who are surgically sterile, who have medically documented ovarian failure, or who are at least 1 year postmenopausal. For females: 2 of the following contraceptive methods, with at least 1 being a barrier method: - Hormonal contraceptives for = 3 months before screening - Intrauterine device (IUD) in place = 3 months before screening - Double-barrier methods (use of condom [male partner] with either diaphragm with spermicide or cervical cap with spermicide) from screening - Surgical sterilization of the partner (vasectomy = 1 month before screening) For males: - Surgical sterilization (vasectomy = 1 month before screening) or - Both of the following contraceptive methods from screening: - Consistently and correctly use a condom - Partner must agree to use a hormonal contraceptive or a nonhormonal barrier method (IUD or diaphragm with spermicide or cervical cap with spermicide) Exclusion Criteria: General Exclusions 1. Participation in a clinical trial with, or use of, any investigational agent within 30 days before screening 2. Previous use of LNF. 3. Female patients who are pregnant or breastfeeding. Male patients must confirm that their female sexual partners are not pregnant. Female patients must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 24 hours prior to the start of any investigational agent). Exclusions Based on Disease 4. Current or previous history of decompensated liver disease (Child-Pugh Class B or C) 5. Co-infected with human immunodeficiency virus (HIV) or hepatitis C virus (HCV). 6. Positive results for HIV or HCV Ab at screening. Patients with a positive HCV Ab at screening are allowed if they have completed a curative antiviral regimen and have documented undetectable HCV RNA for at least 3 months before screening and at screening. 7. Past history or current evidence of decompensated liver disease, defined as any of the following at screening: - Bilirubin level = 2.5 mg/dL unless due to Gilbert's disease - Serum albumin level < 3.0 g/dL - International normalized ratio (INR) = 1.5 8. Evidence of significant portal hypertension such as hepatic venous pressure gradient (HVPG) = 10 mmHg; current presence or history of esophageal or abdominal varices, variceal bleeding, or splenomegaly > 12 cm length on imaging 9. Current evidence or history of ascites requiring diuretics or paracentesis, or hepatic encephalopathy 10. Current evidence or history of hepatic encephalopathy 11. Any of the following abnormal laboratory test results at screening: - Platelet count < 90,000 cells/mm3 - White blood cell (WBC) count < 3,000 cells/mm3 - Absolute neutrophil count (ANC) < 1,500 cells/mm3 - Hemoglobin - < 11 g/dL for women - < 12 g/dL for men - Serum creatinine concentration = 1.5 × ULN - Confirmed creatinine clearance (CrCl) < 50 mL/min by Cockroft-Gault or an estimated glomerular filtration rate (eGFR) > 80 mL/min at screening, based on the Cockcroft-Gault equation - Alpha-fetoprotein = 100 ng/mL 12. Evidence of another form of viral hepatitis or another form of liver disease (eg, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, Wilson's disease, alcoholic liver disease, nonalcoholic steatohepatitis, hemochromatosis, alpha-1-anti-trypsin deficiency) 13. History of hepatocellular carcinoma 14. Patients with any of the following: - Current eating disorder or alcohol abuse - Excessive alcohol intake, defined as follows: - > 20 g/day for females (1.5 standard alcohol drinks) or - > 30 g/day for males (2.0 standard alcohol drinks). - A standard drink contains 14 g of alcohol: 360 mL of beer, 150 mL of wine, or 45 mL of spirits - In the opinion of the investigator, an alcohol use pattern that will interfere with study conduct - Drug abuse within the previous 6 months before screening, with the exception of cannabinoids and their derivatives 15. Prior history or current evidence of any of the following: - Immunologically mediated disease (eg, rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) that requires more than intermittent nonsteroidal anti-inflammatory medications for management or that requires use of systemic corticosteroids in the 6 months before screening (inhaled asthma medications are allowed) - Retinal disorder or clinically relevant ophthalmic disorder - Any malignancy within 5 years before screening. Exceptions are superficial dermatologic malignancies (eg, squamous cell or basal cell skin cancer treated with curative intent), or successfully treated in-situ carcinoma of the cervix. - Cardiomyopathy or significant ischemic cardiac or cerebrovascular disease (including history of angina, myocardial infarction, or interventional procedure for coronary artery disease) - Chronic pulmonary disease (eg, chronic obstructive pulmonary disease) associated with functional impairment - Pancreatitis - Severe or uncontrolled psychiatric disorder (eg, depression, manic condition, psychosis, acute and/or chronic cognitive dysfunction, suicidal behavior, and relapse of substance abuse) - Bone marrow or solid organ transplantation 16. Other significant medical condition that may require intervention during the study. Patients with any serious condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed. Patients for whom participation in the study would increase their risk. Exclusions Based on Concurrent Medication Use 17. Any prescription or herbal product that is not approved by the investigator 18. Therapy with an immunomodulatory agent, IFN-alfa (IFN alfa-2a or IFN alfa-2b, or pegylated IFN alfa-2a or alfa-2b), cytotoxic agent, or systemic corticosteroids within 12 months before screening and during the study 19. Use of heparin or warfarin during the study 20. Systemic antibiotics, antifungals, or antivirals for treatment of active infection other than HBV within 14 days before study randomization or during the study 21. Long-term treatment (> 2 weeks) before or during the study with agents that have a high risk for nephrotoxicity or hepatotoxicity unless it is approved by the medical monitor 22. Receipt of systemic immunosuppressive therapy within 3 months before screening or during the study 23. History or evidence for any intolerance or hypersensitivity to LNF, RTV, or other substances that are part of the study drug 24. Concomitant use of any of the following: - Medications or foods that are known moderate or strong inducers or inhibitors of CYP3A4 - Drugs known to prolong the PR or QT interval unless otherwise described in this protocol - Statins, due to inhibition of mevalonate synthesis, which reduces protein prenylation 25. Concomitant use of medications contraindicated in the prescribing information for RTV |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Eiger BioPharmaceuticals |
Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, Winters MA, Subramanya G, Cooper SL, Pinto P, Wolff EF, Bishop R, Ai Thanda Han M, Cotler SJ, Kleiner DE, Keskin O, Idilman R, Yurdaydin C, Glenn JS, Heller T. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167-74. doi: 10.1016/S1473-3099(15)00074-2. — View Citation
Yurdaydin C, et al. Optimizing the Prenylation Inhibitor Lonafarnib Using Ritonavir Boosting in Patients with Chronic Delta Hepatitis. EASL 2015, Abstract 0118.
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Change from baseline in HDV viral load at Week 72 visit (end of follow-up) | HDV RNA viral load will be quantified with a real-time qPCR assay with a lower limit of quantification (LLOQ) of 14 IU/mL | 72 weeks | No |
| Secondary | Change from baseline in HDV viral load at Week 48 visit (EOT) | 48 weeks | No | |
| Secondary | Proportion of patients with histological response | Histological response defined as an improvement in liver histology by at least 2 points in the Hepatitis Activity Score (HAI) with improvement or no worsening of the fibrosis score, at the EOT compared with baseline | 72 weeks | No |
| Secondary | Proportion of patients with sustained virologic response: HDV RNA below the LLOQ 12 weeks after EOT | 60 weeks | No | |
| Secondary | Proportion of patients with sustained virologic response: HDV RNA below the LLOQ 24 weeks after EOT | 72 weeks | No | |
| Secondary | Emergence of HDV resistance mutations | 48 weeks | Yes | |
| Secondary | Number of participants with treatment-emergent changes in clinical laboratory findings | 48 weeks | Yes | |
| Secondary | Number of participants with treatment-emergent / treatment-related adverse events (AE) and serious adverse events | 48 weeks | Yes | |
| Secondary | Number of participants with AE leading to early discontinuation of study treatment or dose reduction | 48 weeks | Yes |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02527707 -
Titrating-Dose of Lonafarnib in Combination With Ritonavir
|
Phase 2 | |
| Withdrawn |
NCT02968641 -
A Study of Lonafarnib With or Without Ritonavir in Patients With HDV
|
Phase 2 |